Bravias Capital Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$226K Buy
+7,938
New +$211K 0.13% 95
2026
Q2
– Sell
-7,508
Closed -$211K – 100
2026
Q1
$211K Buy
+7,508
New +$200K 0.14% 91

Other funds holding PFE

Bravias Capital Group's PFE Position: Q3 2026 in Review

Bravias Capital Group opened a new position in Pfizer (PFE) in Q3 2026: 7,938 shares worth $226K. The stake represents 0.13% of the portfolio and ranks #95 among its holdings. This is a return to the name: Bravias Capital Group previously reported a position in PFE as recently as Q1 2026.

Bravias Capital Group first reported a position in PFE in Q1 2026 and has held it in 2 quarters since. 2,904 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Bravias Capital Group held 7,938 shares of Pfizer worth $226K as of Q3 2026.
  • Pfizer was a new Bravias Capital Group position in Q3 2026.
  • Pfizer made up 0.13% of Bravias Capital Group's portfolio in Q3 2026, its #95 holding.
  • Bravias Capital Group first reported a position in Pfizer in Q1 2026 and has held it in 2 quarters since.
  • 2,904 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Bravias Capital Group's 13F filing for Q3 2026, filed 12 Nov 2026.